Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price89.04 EUR
Fair value86.00
Ethical score70.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-08-28Read Accumulation64.08+39.0% to today ✓Markup gives way to Accumulation first Accumulation read since July
2026-07-27Read Markup64.08+39.0% to today ✓Accumulation gives way to Markup
2026-07-02Read Accumulation64.08+39.0% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Eurofins Scientific holds its Accumulation at $89.04. The statistical read favours the buyers, held for 37 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 37 days
Price at the screen
$89.04
Valuation
30.61 trailing · 16.77 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.85
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio 40.3%
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
40.34%
Below 33%
Interest-bearing debt is 40.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
7.20%
Below 33%
Cash held in interest-bearing accounts and securities is 7.2% of assets, under the one-third limit.
Pass
Receivables
9.99%
Below 49%
Money owed to the company is 10.0% of assets, under the 49% limit.
Pass
Revenue purity
2.01%
Below 5%
Only 2.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Eurofins Scientific's business is in a permissible area, but its interest-bearing debt is about 40% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ERF.PA's ethical verdict changes
Today ERF.PA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades above our 86.00 EUR fair value estimate, 4.30% revenue growth.
Fair value range in EUR, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 3.5% above the base estimate.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Luxembourg and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ERF.PA trades on EURONEXT PARIS (the company is based in Luxembourg). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Accumulation$84.70+8.5%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 30% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it buy, with a mean price target of $71.
2026-10-16Accumulation$78.06+0.0%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it buy, with a mean price target of $71.
2026-10-02Accumulation$78.06+21.8%Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 21.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it buy, with a mean price target of $71. Since the last review it its composite score eased.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it buy, with a mean price target of $71.
2026-07-27Markup · changed$64.08+0.0%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it buy, with a mean price target of $71.
2026-07-18Accumulation$64.08+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (14 analysts) rates it buy, with a mean price target of $71.
2026-07-03Accumulation$64.08+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$64.08Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$58.52
+11.8%
·
$1,118
+11.8%
2 months
$63.41
+3.2%
$0.72
$1,043
+4.3%
3 months
$62.44
+4.8%
$0.72
$1,059
+5.9%
6 months
$56.79
+15.2%
$0.72
$1,165
+16.5%
1 year
$58.13
+12.5%
$0.72
$1,138
+13.8%
2 years
$52.30
+25.1%
$1.82
$1,286
+28.6%
3 years
$56.81
+15.2%
$2.82
$1,201
+20.1%
5 years
$80.44
-18.7%
$4.50
$869
-13.1%
Historical returns from market close data. Past performance does not guarantee future results.
The Ledger's Promise
This entry now belongs to the ledger. Whatever ERF.PA does next, these words stay.
Eurofins Scientific · ERF.PA · Accumulation · $89.04
Recorded 2026-11-05 · before the outcome · scored mechanically